Banco Santander S.A. Acquires 22,300 Shares of Bristol-Myers Squibb (NYSE:BMY)

Banco Santander S.A. raised its holdings in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 4.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 475,898 shares of the biopharmaceutical company's stock after purchasing an additional 22,300 shares during the quarter. Banco Santander S.A.'s holdings in Bristol-Myers Squibb were worth $24,623,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of BMY. Reston Wealth Management LLC acquired a new stake in shares of Bristol-Myers Squibb in the 3rd quarter valued at about $25,000. Hollencrest Capital Management grew its holdings in shares of Bristol-Myers Squibb by 61.3% in the third quarter. Hollencrest Capital Management now owns 492 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 187 shares in the last quarter. Kennebec Savings Bank bought a new position in Bristol-Myers Squibb during the third quarter valued at $28,000. Darwin Wealth Management LLC bought a new position in Bristol-Myers Squibb during the third quarter valued at $29,000. Finally, Valued Wealth Advisors LLC grew its holdings in Bristol-Myers Squibb by 1,168.1% during the third quarter. Valued Wealth Advisors LLC now owns 596 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 549 shares during the period. Institutional investors and hedge funds own 76.41% of the company's stock.

Insiders Place Their Bets

In other news, SVP Phil M. Holzer sold 700 shares of the company's stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $55.62, for a total transaction of $38,934.00. Following the sale, the senior vice president now owns 11,760 shares in the company, valued at $654,091.20. This represents a 5.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Samit Hirawat purchased 1,830 shares of the company's stock in a transaction that occurred on Friday, November 1st. The stock was acquired at an average price of $54.67 per share, for a total transaction of $100,046.10. Following the purchase, the executive vice president now owns 62,109 shares in the company, valued at $3,395,499.03. This trade represents a 3.04 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 0.09% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on BMY. Barclays increased their price objective on Bristol-Myers Squibb from $42.00 to $43.00 and gave the stock an "underweight" rating in a research report on Monday, October 7th. Wolfe Research initiated coverage on Bristol-Myers Squibb in a research note on Friday, November 15th. They set a "peer perform" rating on the stock. Daiwa Capital Markets raised Bristol-Myers Squibb from a "neutral" rating to an "outperform" rating in a research note on Wednesday, November 13th. TD Cowen lifted their price objective on Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a "hold" rating in a research report on Monday, October 7th. Finally, StockNews.com upgraded shares of Bristol-Myers Squibb from a "buy" rating to a "strong-buy" rating in a report on Monday, July 29th. Two research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, two have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $54.07.

Bristol-Myers Squibb Trading Up 0.6 %

BMY stock traded up $0.34 on Thursday, hitting $58.22. 5,462,640 shares of the company were exchanged, compared to its average volume of 14,395,333. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $61.08. The business's fifty day moving average is $53.46 and its two-hundred day moving average is $47.61. The stock has a market capitalization of $118.08 billion, a price-to-earnings ratio of -16.22, a price-to-earnings-growth ratio of 15.62 and a beta of 0.44.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.49 by $0.31. The business had revenue of $11.89 billion for the quarter, compared to analysts' expectations of $11.26 billion. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The company's revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter last year, the company earned $2.00 EPS. As a group, research analysts forecast that Bristol-Myers Squibb will post 0.93 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Friday, October 4th were paid a $0.60 dividend. The ex-dividend date was Friday, October 4th. This represents a $2.40 annualized dividend and a dividend yield of 4.12%. Bristol-Myers Squibb's payout ratio is -66.85%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.